



Project visit · outdoor planning display

COMPANY PROFILE · SEPTEMBER 2026

A pharmaceutical manufacturing project being developed in Boten, Lao PDR.

Who the company is, where the project stands, what is planned, and how professional enquiries are handled — stated at the stage the project has actually reached.

Identity and current stage

Luang Pharma is the brand of the company developing a pharmaceutical manufacturing facility in Boten Economic Zone, Lao PDR. The immediate programme is the establishment of that facility and the foundations needed for future pharmaceutical operations.

LEGAL NAME	BRAND
Luang Pharma Co., Ltd	Luang Pharma
ENTERPRISE CODE / TIN	DATE OF ENTERPRISE REGISTRATION
364321674000	9 July 2026
PROJECT LOCATION	CURRENT STAGE
Boten Economic Zone, Lao PDR	Construction and fit-out · in progress

Registration particulars as published in the company information notice, <https://luangpharma.com/legal/company-information/>, which also carries the registered address. Company registration is separate from any manufacturing authorisation, quality certification or medicine registration, none of which this profile states.

Stage boundary

A construction project, installed equipment, qualified systems, a manufacturing authorisation, a registered medicine and an available commercial supply are different milestones. This profile does not collapse them into one claim. No manufacturing licence, GMP certificate, product registration or commissioned line is represented here as issued.

Three connected workstreams

WORKSTREAM	WHAT IT COVERS
Physical Boten project	Facility development, planned production modules, implementation sequencing and the evidence needed before routine operation.
Generic product portfolio	Public development records organised by generic identity and presentation. Portfolio inclusion does not establish a manufacturing route, approval or availability.
Market and partner assessment	Product- and destination-specific discussion of regulatory roles, supply-chain responsibilities and the information needed before a commercial pathway can be defined.

Where the project stands

Construction and fit-out is in progress, with equipment installation and qualification as the next step. Status reviewed 13 September 2026.

	PHASE	STATUS	TIMING
01	Facility design	Complete	
02	Construction and fit-out	In progress	Target Q4 2026 · indicative
03	Equipment installation and qualification	Planned	Target Q1 2027 · indicative
04	Process and system validation	Planned	Target Q2 2027 · indicative
05	Manufacturing licence application	Planned	Target Q3 2027 · indicative
06	Regulatory inspection	Planned	Target Q4 2027 · indicative
07	First commercial batch	Planned	Target Q1 2028 · indicative

Quarters are indicative targets, reviewed as the project advances, and are not regulatory commitments. A phase is marked complete only when the company has confirmed it.

Dated project record

15 June 2026	Boten manufacturing project brief issued
24 July 2026	Boten Economic Zone announces Luang Pharma’s agreement to locate in the Haichuan Industrial Park



Project representatives during a project discussion · no regulatory endorsement or exact event date asserted

The initial manufacturing plan

The June 2026 project brief describes two planned production modules. They are a development plan: no installed equipment, validated process or production capacity is claimed.

MODULE 01 · PLANNED

Formulation and filling

Filling activity including lyophilisation, for five presentation families in the source plan:

- Lyophilised vials
- Dual-chamber cartridges
- Single-chamber lyophilised cartridges
- 10 mL oil-based vial injections
- 1 mL ampoules

MODULE 02 · PLANNED

Protein raw-material production and purification

A separate planned module for protein raw-material production and purification. The source does not by itself establish a validated process, specific product, installed state or authorised production scope.

Planned capabilities catalogue

Beyond the two modules, the website publishes a catalogue of 75 planned service domains in 13 groups. It is a proposed expansion of scope for technical discussion; listing an entry does not establish installed equipment, accepted work or service availability, and no service has a start date of its own.

GROUP	DOMAINS
Product & process development	5
Oral solid dosage forms	6
Liquid dosage forms	4
Semi-solids & specialised presentations	4
Sterile products & aseptic filling	10
Ophthalmic, inhaled & other delivery forms	5
Drug substance & biological inputs	5

GROUP	DOMAINS
Specialist manufacturing domains	4
Packaging, assembly & serialisation	6
Analytical & stability services	8
Technology transfer & contract manufacturing	6
Regulatory & documentation support	6
Materials, logistics & supply support	6

Full catalogue: <https://luangpharma.com/capabilities/>

Portfolio overview

A development roadmap of generic identities and proposed presentations, organised by category. The records do not establish product approval, a manufacturing route or availability.

178

public development records

168

medicine records

10

device or diagnostic records

16

portfolio categories

CATEGORY	RECORDS
Hospital Injectable Products	33
Anti-Infectives	25
Pediatrics	16
Cardiovascular Medicines	14
Dermatology Products	13
Gastrointestinal Medicines	13
Women's Health	11
Medical Devices & Diagnostics	10
Neurology & Psychiatry	10
Respiratory Medicines	8
Vitamins & Nutrition	7
OTC Products	6
Oncology Supportive Care	5
Diabetes & Metabolic Medicines	4
Essential Medicines	2
Endocrinology & HRT	1

Not marketed

No Luang Pharma product is on the market. The portfolio includes dosage forms beyond the initial planned production modules; a record count is not a product-approval or manufacturing count.

Falsified products and misuse of our name

Any medicine offered today under the Luang Pharma name is not the company's product. Report it through <https://luangpharma.com/legal/falsified-products-and-misuse-of-our-name/>

Trade names and final packaging are not published. Record-by-record detail: <https://luangpharma.com/products/>

Quality system development and evidence

Quality claims are useful only when they identify the product, system, site, evidence and status they support. At the current stage the programme identifies the requirements; implementation has to be evidenced as the project advances.

Claim boundary

No current GMP certificate, pharmaceutical quality system in operation, qualified utility, validated production process, testing laboratory or released commercial batch is asserted by this profile.

The framework the programme is organised around

Document control Controlled versions, approval and access to the records a system uses.	Training and responsibility Role-specific work tied to competence, documented training and accountable decisions.	Supplier and material quality Material identity, supplier assessment and traceability kept connected.
Qualification and validation Defined systems, protocols, acceptance criteria and executed evidence.	Deviation and corrective action Events recorded, causes investigated, corrective and preventive actions evaluated.	Change control The impact of a proposed change assessed before it is approved and implemented.
Data integrity Attributable, complete and reviewable records throughout their lifecycle.	Analytical and stability work Methods, specifications and study conclusions tied to the exact product and container.	Review and release decisions Responsibilities and the evidence needed for any future batch decision.

The product evidence chain

Defined product → controlled process → generated evidence → quality review → regulatory use. Evidence stays connected to the exact product and use it was generated for: active substance, formulation, strength, container and closure, site, process version, specification, methods, batch records, stability package and intended market.

How to reach the company

The company publishes no email address or telephone number. The professional contact form on the website is the contact route; name the subject of the enquiry in the message so it reaches the right reviewer.

Professional contact form	https://luangpharma.com/contact/
Partnering and market discussions	https://luangpharma.com/partnering/
Suppliers of equipment, materials and services	https://luangpharma.com/suppliers/
Company information and registration particulars	https://luangpharma.com/legal/company-information/
Project roadmap	https://luangpharma.com/journey/

Verifying communications

Use the published domain and the contact form on it to verify unexpected messages, offers or requests. The website and this profile do not take payment, conclude supply contracts, appoint distributors or provide product-authentication results.

This profile is generated from the website's source data and reflects the project status reviewed on 13 September 2026. Where the two differ, the website is the current record. Published for information; it is not legal or medical advice, an offer of supply or a regulatory submission.